Aliases:This biomarker is also known as:
- Tyrosine kinase-type cell surface receptor HER2,
- Proto-oncogene Neu,
- Proto-oncogene c-ErbB-2,
- v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog),
- MLN 19,
- Receptor tyrosine-protein kinase erbB-2,
- v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian),
- Metastatic lymph node gene 19 protein,
From NCBI Gene: This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
No additional data available.
Ninety biomarkers were measured using a series of multiplexed immunoassays and results analyzed by the EDRN data management center splitting the cases and controls into training and validation sets, excluding subjects with DCIS or atypical hyperplasia from the training phase. We found little evidence that any of these markers can discriminate women with invasive cancer from those with benign breast conditions.
|QA State:||Under Review|
|QA State:||Under Review|
Amplification and/or overexpression of the ERBB2 gene has been reported in numerous cancers, including breast and ovarian tumors. Studies have suggested that ERBB2 overexpression represented a major negative prognostic indicator for patients with several human cancers, including endometrial carcinomas
Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.
- The state of molecular biomarkers for the early detection of lung cancer.
- Autoantibodies in lung cancer: possibilities for early detection and subsequent cure.
- Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma.
- HGNC entry for ERBB2 from Genenames
- KEGG entry for ERBB2 from Genome.jp
- Entrez entry for ERBB2 all NCBI Databasese
- Human GEO Profiles for ERBB2 from NCBI GEO Profiles
- Human Geo Datasets containing term ERBB2 from NCBI GEO Datasets
- GWAS Study Datasets containing gene ERBB2 from GWAS
- Human Single Nucleotide Polymorphisms info for ERBB2
- Human Gene(s) with 'ERBB2' as Gene Name/Alias
- Human Gene RefSeq for ERBB2 from NCBI
- UniProtKB/Swiss-Prot entry for ERBB2 from Uniprot
- Human Protein RefSeq for ERBB2 from NCBI
- FDA web page describing approval of ERBB2
|UniProt Accession #:||P04626|
|Mutated Sites Count:||1|
|Associated Pubmed ID Count||66|
|Affected Protein Function Sites Count:||1|